All Updates

All Updates

icon
Filter
Partnerships
Product updates
Insilico Medicine delivers second preclinical candidate compound to Fosun Pharma
AI Drug Discovery
Jul 5, 2024
This week:
Partnerships
Intuitive AI partner with Moda Center to implement Oscar Sort recycling technology
Waste Recovery & Management Tech
Yesterday
Management news
Funding
Minze Health raises USD 5.3 million in funding for product and market expansion; appoints new VP
Preventive Healthcare
Yesterday
Partnerships
Firefly Aerospace partners with True Anomaly for Space Force rapid-response mission launches
Space Travel and Exploration Tech
Yesterday
Funding
zkPass raises USD 12.5 million in Series A funding
Enterprise Blockchain Solutions
Yesterday
Partnerships
Ontada partners with Microsoft to process unstructured oncology data using Azure AI
Clinical Trial Technology
Yesterday
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
AI Drug Discovery

AI Drug Discovery

Jul 5, 2024

Insilico Medicine delivers second preclinical candidate compound to Fosun Pharma

Partnerships
Product updates

  • AI-powered drug developer Insilico Medicine has completed the second preclinical candidate compound (PCC) in collaboration with Fosun Pharma. This compound is potentially a new therapeutic for treating solid tumors using a synthetic lethal strategy. The companies expect to submit the candidate for pre-IND application by Q4 2024.

  • The compound targets DNA damage repair mechanisms, a significant aspect of tumor therapy. The process leveraged Insilico’s PandaOmics, an AI target identification engine, and Life Star 1, an AI-operated lab. Chemistry42, another AI tool, created compounds expressly for the target. The compound is claimed to have shown promising results in preclinical studies, with anti-tumor efficacy and impressive ADMET properties. Fosun Pharma plans to take on the compound for further research and development after Insilico advances it to the IND-enabling stage.

  • Analyst QuickTake : The partnership between Insilico Medicine and Fosun Pharma was established in January 2022 . It was aimed to develop multiple drug targets, including Insilico’s Glutaminyl-peptide cyclotransferase-like (QPCTL) program, and to develop Fosun’s internal drug development programs using Insilico's PandaOmics and Chemistry42 platforms.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.